Market Insights Health Pharmaceuticals Vaccines

Other Vaccines - Tunisia

Tunisia

In Tunisia, the revenue in the market of Other Vaccines market is projected to reach US$11.75m in 2024.
Looking ahead, it is expected to exhibit a compound annual growth rate (CAGR 2024-2029) of 9.81%, leading to a market volume of US$18.76m by 2029.
When compared globally, United States is projected to generate the highest revenue in this market, amounting to US$24,730.00m in 2024.
Tunisia is witnessing a growing demand for other vaccines, driven by an increased awareness of the importance of immunization among its population.

Key regions: Australia, Brazil, United Kingdom, Europe, Canada

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for other vaccines in Tunisia has been on the rise in recent years.

Customer preferences: Tunisians have become more health-conscious and are increasingly aware of the importance of preventive healthcare. As a result, there has been a significant increase in demand for other vaccines, which offer protection against diseases such as meningitis, pneumonia, and hepatitis.

Trends in the market: One of the key trends in the other vaccines market in Tunisia is the growing demand for combination vaccines. These vaccines offer protection against multiple diseases in a single shot, which is convenient for patients and helps to reduce healthcare costs. Another trend is the increasing availability of vaccines in private clinics and hospitals, which is contributing to the growth of the market.

Local special circumstances: Tunisia has a relatively high incidence of certain diseases, such as meningitis, which has contributed to the demand for other vaccines. In addition, the government has implemented several initiatives to promote vaccination, including free vaccination campaigns for children.

Underlying macroeconomic factors: Tunisia has a relatively stable economy, which has helped to support the growth of the other vaccines market. In addition, the government has made significant investments in the healthcare sector, which has improved access to healthcare services and contributed to the growth of the market. However, the market is still relatively small compared to other countries in the region, and there is significant room for growth.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.